Table 1.
Demographic characteristics, clinical and laboratory data, and comorbidities of the 92 CKD patients and the 20 controls.
| Parameters | CKD patients (n = 92) | Controls [20] |
|---|---|---|
| Age (years) | 65.8 ± 12.45 | 35 ± 6 |
| Gender (male), n % | 51 (55.4%) | 6 (30%) |
| BMI (kg/m2) | 47.29 ± 25.68 | 22.7 ± 2.0 |
| SBP (mmHg) | 142 ± 19 | 111 ± 12 |
| DPB (mmHg) | 81 ± 11 | 67 ± 8 |
| Hypertension, n % | 80 (74%) | 0 |
| Diabetes mellitus, n % | 26 (28.3%) | 0 |
| History of CAD, n % | 25 (27%) | 0 |
| Statin treatment, n % | 33 (36%) | 0 |
| eGFR/CKD-EPI (ml/min/1.73 m2) | 47.3 ± 25.7 | 89.5 ± 18.3 |
| UPR (mg/24 h) | 323 (140, 1148) | — |
| T-Chol (mg/dl) | 209 ± 47 | 172 ± 27 |
| TG (mg/dl) | 163 ± 88 | 67 ± 32 |
| HDL (mg/dl) | 52 ± 15 | 57 ± 11 |
| LDL (mg/dl) | 124 ± 39 | 102 ± 21 |
| Lp(a) (mg/dl) | 11.1 (8.0, 29.3) | 8 (1-24) |
| APO-A1 (mg/dl) | 139 ± 30 | 159 ± 23 |
| APO-B (mg/dl) | 93 ± 28 | 65 ± 15 |
| Albumin (mg/dl) | 4.23 ± 0.40 | 4.4 ± 0.30 |
| Uric acid (mg/dl) | 6.82 ± 1.64 | 5.1 ± 1.35 |
| PTH pg/ml | 74 (47, 121) | — |
| Hb (g/dl) | 13.0 ± 1.6 | 13.6 ± 1.4 |
| HbA1c (%) | 6.1 (5.7, 7.2) | — |
| LVMI (g/m2) | 135.7 ± 47.1 | — |
| EF (%) | 69 ± 10 | — |
| FS (%) | 37 ± 8 | — |